Filtered By:
Specialty: Cardiology
Drug: Pradaxa
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 478 results found since Jan 2013.
The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery
ConclusionDabigatran 110 mg twice daily was cost neutral for patients in the MANAGE trial. Our cost findings support the use of dabigatran 110 mg twice daily in patients with MINS.Trial RegistrationClinicalTrials.gov identifier number NCT01661101.
Source: American Journal of Cardiovascular Drugs - July 26, 2021 Category: Cardiology Source Type: research
Safety of High-Dose Dabigatran in Elderly and Younger Patients with a Low Bleeding Risk: A Prospective Observational Study
Conclusions: Our results suggest that Dabigatran 150 mg twice a day can be safely used among elderly AF patients with low bleeding risk.Cardiology
Source: Cardiology - June 11, 2021 Category: Cardiology Source Type: research
Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
CONCLUSION: Dabigatran, rivaroxaban, and apixaban appear to be superior to warfarin in both efficacy and safety in Asians with non-valvular AF.PMID:33968307 | PMC:PMC8069517 | DOI:10.4330/wjc.v13.i4.82
Source: World Journal of Cardiology - May 10, 2021 Category: Cardiology Authors: Wei-Jia Li Paraschos Archontakis-Barakakis Leonidas Palaiodimos Dimitrios Kalaitzoglou Lazaros Tzelves Apostolos Manolopoulos Yu-Chiang Wang Stefanos Giannopoulos Robert Faillace Damianos G Kokkinidis Source Type: research
